The Zacks Analyst Blog Highlights: Zumiez, Mylan, AbbVie, Sant...

(Comtex SmarTrend(R)) Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $31.15 to a high of $32.09. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $31.89 on volume of 8.4 million ...

(Financial News Network On) Mylan (NASDAQ:MYL) is one of today's biggest movers, up 1.8% to $31.80. The S&P is trading higher by 0.4% to 1,676 and the Dow is trading 0.5% higher to 15,462. Over the past year, Mylan has traded in a range of $15.49 ...

Mylan Inc. has announced that the Court of Appeals for the Federal Circuit has ruled in favour of Mylan Specialty LP, f/k/a Dey Pharma, LP. It has reversed the District Court's decision invalidating five of Mylan's patents related to Perforomist.

This report provides all the information you require to better understand Mylan and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the ...

(Comtex SmarTrend(R)) Two weeks ago on May 2nd, 2013 Mylan (NASDAQ:MYL) reported earnings and analysts, on average, expected earnings of $0.61 on sales of $1.7 billion. The company actually reported EPS of $0.62 on sales of $1.6 billion, beating ...

Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources

(Financial News NetwFork O) Mylan (NASDAQ:MYL) traded at a new 52-week high today of $31.89. Approximately 2.9 million shares have changed hands today, as compared to an average 30-day volume of 5.7 million shares. Mylan has overhead space with ...

The Lokayukta report in Karnataka exposed illegalities, irregularities and crime by mining mafia in connivance with politicians and bureaucrats Madhya Pradesh goes the Gujarat way for power It has tied up long-term contracts and has undertaken reforms, just ...

Mylan's Robert J. Coury is the highest-paid executive at public companies based in the Tri-State region for the third year in a row, easily outdistancing PPG Industries' Charles E. Bunch, who finished second. The Cecil generic drugmaker provided Mr.